


Anipamil

Cat. No.:	HY-U00044
CAS No.:	83200-10-6
Molecular Formula:	C ₃₄ H ₅₂ N ₂ O ₂
Molecular Weight:	520.79
Target:	Calcium Channel
Pathway:	Membrane Transporter/Ion Channel; Neuronal Signaling
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Anipamil is a long-acting calcium channel blocker, used for the treatment of cardiovascular disease.
In Vivo	<p>Anipamil (40 mg, p.o.)-treated 2K-1C rabbits reveal absent or negligible intimal thickening and a decrease of postnatal-type SMC from the underlying media. Anipamil inhibits the growth of SMC accompanied by the expression of SM-MyHC in all SMC, ie, the appearance of a more differentiated cell phenotype compared to control cultures^[1]. In the arrhythmic assay, anipamil (1.0 mg/kg + 0.10 mg/kg/min infusion, n=8 or 5.0 mg/kg + 0.50 mg/kg/min infusion, n=12) reduces VT but not VF^[2]. In rats with subtotal (five-sixths) nephrectomy treated with anipamil (0.5 mg/kg/day, p.o.), the mortality is less, and the mean arterial blood pressure is also more well controlled, and the serum creatinine concentration is lower than control group. The anipamil (2 mg/kg/day)-treated group exhibits significantly greater protection of renal function than does the hydralazine-treated group for the same level of blood pressure control^[3].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>

PROTOCOL

Animal Administration ^[3]	<p>Preliminary studies are performed to determine the anipamil dose response. Anipamil is mixed with food to give a dose of 0.5, 2 or 5 mg/kg/day. One week after five-sixths nephrectomy, rats are paired according to renal function, blood pressure and body weight. Rats are then pair-fed and receive either the long-acting calcium channel blocker anipamil (2 mg/kg/day in food, n=20) or placebo (n=20).</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>
---	--

REFERENCES

- [1]. Pauletto P, et al. Anipamil prevents intimal thickening in the aorta of hypertensive rabbits through changes in smooth muscle cell phenotype. *Am J Hypertens.* 1996 Jul;9(7):687-94.
- [2]. Pugsley MK, et al. Effects of anipamil, a long acting analog of verapamil, in pigs subjected to myocardial ischemia. *Life Sci.* 1995;57(12):1219-31.
- [3]. Jarusiripat C, et al. Effect of long-acting calcium entry blocker (anipamil) on blood pressure, renal function and survival of uremic rats. *J Pharmacol Exp Ther.* 1992 Jan;260(1):243-7.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA